Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation

The associations between B-cell lymphoma 2 (BCL-2) and multi-drug resistance associated P-glycoprotein (MDR1) expressions and chemoradiotherapy outcome of patients with non-small cell lung cancer (NSCLC) were analysed. Thirty-two NSCLC patients were treated with paclitaxel-based chemoradiotherapy. T...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2011-04, Vol.31 (4), p.1431-1436
Main Authors: Maráz, Anikó, Furák, József, Pálföldi, Regina, Eller, József, Szántó, Erika, Kahán, Zsuzsanna, Thurzó, László, Molnár, József, Tiszlavicz, László, Hideghéty, Katalin
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
ATP Binding Cassette Transporter, Sub-Family B
ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism
Carboplatin - administration & dosage
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - secondary
Carcinoma, Non-Small-Cell Lung - therapy
Cisplatin - administration & dosage
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Female
Humans
Immunoenzyme Techniques
Lung Neoplasms - metabolism
Lung Neoplasms - secondary
Lung Neoplasms - therapy
Male
Middle Aged
Paclitaxel - administration & dosage
Prospective Studies
Proto-Oncogene Proteins c-bcl-2 - metabolism
Radiotherapy Dosage
Survival Rate
Taxoids - administration & dosage
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The associations between B-cell lymphoma 2 (BCL-2) and multi-drug resistance associated P-glycoprotein (MDR1) expressions and chemoradiotherapy outcome of patients with non-small cell lung cancer (NSCLC) were analysed. Thirty-two NSCLC patients were treated with paclitaxel-based chemoradiotherapy. The tumour expressions of BCL-2 and MDR1 were analysed by means of immunohistochemistry with regard to the clinical response and survival data. Partial remission and stable disease were achieved in 19 (59%) and 10 (31%) cases, respectively. Significant differences in progression-free survival were observed between responders and non-responders (13.7 vs. 6.0 months, p=0.028), and between patients with or without a gross tumour volume (GTV) shrinkage (GTV(>50) 13.7 vs. 6.0 months, p=0.009). Overexpression of BCL-2 and of MDR1 was observed in 6 (21.4%) cases each. Overexpression of both markers together was associated with poor response (GTV reduction: p=0.005; RECIST: p=0.023) and lower progression-free survival (overexpression of both, low expression of both, mixed: 3.1, 13.4, 4.1 months, respectively, p
ISSN:1791-7530